The impact of preoperative ASA-physical status on postoperative complications and long-term survival outcomes in gastric cancer patients
F. Rosa, A.P. Tortorelli, G. Quero, F. Galiandro, C. Fiorillo, L. Sollazzi, S. Alfieri Department of Digestive Surgery, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy. fausto.rosa@policlinicogemelli.it
OBJECTIVE: The aim of this study was to investigate the impact of the preoperative American Society of Anesthesiologists-Physical status (ASA-PS) on both the short-term and long-term outcomes in patients with Gastric Cancer (GC).
PATIENTS AND METHODS: In a retrospective observational study, a total of 473 GC patients were divided into the following 3 groups: ASA 1, ASA 2, and ASA 3-4.
RESULTS: The ASA 3-4 group included significantly older patients compared to the other groups (p<0.0001). In ASA 1 patients, there was a higher number of lymph nodes dissected (p=0.006), and more patients received adjuvant treatment (p<0.001). In the three groups, no difference regarding the postoperative surgical and medical complications (p=0.29 and p=0.1, respectively) nor in terms of mortality rate (p=0.17) were demonstrated. The multivariate analysis showed that age, tumor stage, number of lymph nodes dissected, positive lymph nodes, adjuvant treatments, and postoperative surgical complications were significant predictive factors for mortality. Five-year overall and disease-free survival for ASA 1, ASA 2, and ASA 3-4 groups was 56%, 57.6%, and 44%, respectively; and 37%, 44.3%, and 39.2%, respectively.
CONCLUSIONS: Preoperative ASA-PS alone cannot serve as a direct operative risk indicator for GC patients.
Free PDF DownloadThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License
To cite this article
F. Rosa, A.P. Tortorelli, G. Quero, F. Galiandro, C. Fiorillo, L. Sollazzi, S. Alfieri
The impact of preoperative ASA-physical status on postoperative complications and long-term survival outcomes in gastric cancer patients
Eur Rev Med Pharmacol Sci
Year: 2019
Vol. 23 - N. 17
Pages: 7383-7390
DOI: 10.26355/eurrev_201909_18846